BiotechTube

mRNA-1283.251 Variant-containing Formulation

ApprovedRecruiting
2 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

COVID-19

Conditions

COVID-19

Trial Timeline

Jul 21, 2025 → May 11, 2026

NCT ID
NCT07089706

About mRNA-1283.251 Variant-containing Formulation

mRNA-1283.251 Variant-containing Formulation is a approved stage product being developed by Moderna for COVID-19. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07089706. Target conditions include COVID-19.

What happened to similar drugs?

6 of 20 similar drugs in COVID-19 were approved

Approved (6) Terminated (4) Active (12)
✅AZD1222AstraZenecaApproved
✅AZD1222AstraZenecaApproved
✅Rivaroxaban 10 mgBayerApproved
✅Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)NovavaxApproved
✅protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineNovavaxApproved
✅NVX-CoV2705 + PlaceboNovavaxApproved
🔄mRNA-1283.222ModernaPhase 3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07089706ApprovedRecruiting

Competing Products

20 competing products in COVID-19

See all competitors
ProductCompanyStageHype Score
mRNA-1283.222ModernaPhase 3
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
Moderna COVID-19 VaccineModernaPreclinical
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
31
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Gimsilumab + PlaceboRoivant SciencesPhase 2
32
Icosapent ethylAmarin CorporationPhase 2
25
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
40
InfliximabCelltrionPhase 2
35
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
32
Enzalutamide PillAstellas PharmaPhase 2
27
S-892216 + PlaceboShionogiPhase 2
35
S-892216 + CarbamazepineShionogiPhase 1
29
FOY-305 + PlaceboOno PharmaceuticalPhase 3
40
DesidustatZydus LifesciencesPhase 2
35
LY3819253 + PlaceboEli LillyPhase 1
29
Bamlanivimab + Etesevimab + Placebo + VIR-7831 + BebtelovimabEli LillyPhase 2
35